IP that matters: behind Orexo’s patent win against generic giant (NLS Days)

IP that matters: behind Orexo’s patent win against generic giant (NLS Days)
date
October 13, 2025
TIme
16:30 - 17:30 CEST
Address

Flow Stage, Svenska Mässan, Gothenburg

When a challenger comes for your life’s work, how do you fight back and win?

At Nordic Life Science Days, you’ll get a rare inside look at Orexo’s decisive US patent litigation victory over Sun Pharma, a case that proves the power of a rock-solid IP strategy in protecting both innovation and patient impact. 

Hear from those who lived it: 

  • Orexo – on the effective use of IP to meet its business objectives, safeguarding lifechanging treatments for opioid dependence; 
  • Steptoe -  US litigators who brought and successfully argued the case before the court; and
  • Potter Clarkson – Orexo’s patent attorneys who had a key, central role in preparing the ground for that success

Join us on the Flow Stage at 16:30, Monday 13 October for an insightful session.

Because when innovation is under fire, strategy is everything. 

Latest News

Priority patent applications for biotech and chemistry startups

Priority patent applications for biotech and chemistry startups

The deal killers investors often find too late: An IP lawyer’s guide to investor readiness

The deal killers investors often find too late: An IP lawyer’s guide to investor readiness

Potter Clarkson experts recognised in Lexology Index 2026

Potter Clarkson experts recognised in Lexology Index 2026

HPV-positive oropharyngeal cancer: prevention to precision treatment

HPV-positive oropharyngeal cancer: prevention to precision treatment

Unlocking the future of cleantech

Unlocking the future of cleantech

Supporting Nottingham Pride through pro bono trade mark expertise

Supporting Nottingham Pride through pro bono trade mark expertise

Winning at the EPO: Proven specialists in EPO oppositions

Winning at the EPO: Proven specialists in EPO oppositions

Protecting antibody innovations beyond composition claims

Protecting antibody innovations beyond composition claims

See All News